714255-28-4 Usage
Uses
Used in Pharmaceutical Industry:
4,5,6,7-Tetrahydro-2H-indazole-3-carboxylic acid is used as a reactant for the preparation of 1,4-disubstituted piperidine derivatives. These derivatives have potential applications as 11-βHSD1 inhibitors, which are important targets for the treatment of various metabolic and cardiovascular diseases.
In the synthesis of 1,4-disubstituted piperidine derivatives, 4,5,6,7-Tetrahydro-2H-indazole-3-carboxylic acid serves as a key building block, providing the necessary structural framework for the development of novel inhibitors. These inhibitors can modulate the activity of 11-βHSD1, an enzyme involved in the regulation of glucocorticoid levels, which has been implicated in the pathogenesis of metabolic disorders such as obesity, type 2 diabetes, and cardiovascular diseases.
By leveraging the unique properties of 4,5,6,7-Tetrahydro-2H-indazole-3-carboxylic acid, researchers can design and synthesize new piperidine-based compounds with improved potency, selectivity, and pharmacokinetic profiles. This can lead to the development of more effective therapeutic agents for the treatment of metabolic and cardiovascular diseases, ultimately benefiting patients and healthcare providers alike.
Check Digit Verification of cas no
The CAS Registry Mumber 714255-28-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,1,4,2,5 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 714255-28:
(8*7)+(7*1)+(6*4)+(5*2)+(4*5)+(3*5)+(2*2)+(1*8)=144
144 % 10 = 4
So 714255-28-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H10N2O2/c11-8(12)7-5-3-1-2-4-6(5)9-10-7/h1-4H2,(H,9,10)(H,11,12)
714255-28-4Relevant academic research and scientific papers
Agonist lead identification for the high affinity niacin receptor GPR109a
Gharbaoui, Tawfik,Skinner, Philip J.,Shin, Young-Jun,Averbuj, Claudia,Jung, Jae-Kyu,Johnson, Benjamin R.,Duong, Tracy,Decaire, Marc,Uy, Jane,Cherrier, Martin C.,Webb, Peter J.,Tamura, Susan Y.,Zou, Ning,Rodriguez, Nathalie,Boatman, P. Douglas,Sage, Carleton R.,Lindstrom, Andrew,Xu, Jerry,Schrader, Thomas O.,Smith, Brian M.,Chen, Ruoping,Richman, Jeremy G.,Connolly, Daniel T.,Colletti, Steven L.,Tata, James R.,Semple, Graeme
, p. 4914 - 4919 (2008/02/12)
A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.
